NRP/507 Week 8: Endocrine Drug Therapy Case, sample paper

Starting Basal Insulin for a 56-Year-Old Long-Haul Truck Driver: A Titration Plan Built Around Hypoglycemia, Sleeper-Cab Meals and a Commercial License

[Student Name]

University of Phoenix

NRP/507: Advanced Pharmacology

Week 8 Assignment

[Instructor Name]

[Date]

The patient is a composite written for a model paper. Federal driver rules change; students should check current requirements.

Mr. W., a 56-year-old long-haul truck driver, has lived with type 2 diabetes since his late forties. Despite metformin at 1,000 mg and glipizide at 10 mg, each taken morning and evening, his A1C has risen from 8.4% to 10.1% over a year. He reports thirst and urinating at night, and he has lost 4 kg without trying. His BMI is 33 and his kidney function normal. He is on the road five days at a time and eats at truck stops or from a small cooler in his sleeper cab. He worries that insulin would end his commercial driver's license. This paper explains the plan we built.

Is Insulin Indicated?

The ADA's Standards of Care recommend considering insulin when A1C is above 10% or blood glucose is 300 mg/dL or higher, or when there are symptoms of hyperglycemia or evidence of ongoing catabolism such as weight loss (American Diabetes Association Professional Practice Committee, 2024). Mr. W. meets all three. His weight loss and symptoms suggest insulin deficiency that oral agents are unlikely to overcome. An injectable GLP-1 receptor agonist is also recommended in many patients before or with insulin, but with his current symptoms and weight loss, basal insulin is the more direct response, and a GLP-1 receptor agonist can be added later.

Why Basal Insulin First

Basal insulin added to oral drugs is the usual first insulin in type 2 diabetes. In the 4-T trial, patients adding basal insulin to oral therapy had similar median A1C to those adding prandial insulin but had the lowest rate of hypoglycemia, 1.7 episodes per patient per year compared with 5.7 for prandial, and less weight gain (Holman et al., 2009). Given his job behind the wheel, the lower rate of lows decides the question.

Glargine or NPH

In the Treat-to-Target trial, bedtime glargine and NPH, titrated weekly, brought a similar share of patients, about 60%, to an A1C of 7% or below, but more patients reached that goal without documented nocturnal hypoglycemia on glargine, 33.2% compared with 26.7%, and other categories of symptomatic hypoglycemia were 21% to 48% lower (Riddle et al., 2003). Glargine's flat profile also means he can take it at the same time daily regardless of meals, which suits unpredictable days on the road. For a patient who sleeps in a truck cab 400 miles from home, a low blood sugar at 3 a.m. is not only a side effect but a safety emergency.

The Starting Dose and Titration

I start glargine at 10 units each evening, within the commonly used range of 10 units or 0.1 to 0.2 units/kg for starting basal insulin (American Diabetes Association Professional Practice Committee, 2024). Mr. W. will titrate himself: if his fasting glucose averages above 130 mg/dL for three days, he adds 2 units; if any reading falls below 80 mg/dL, he reduces by 4 units and calls the clinic. The target fasting range is 80 to 130 mg/dL.

Adjusting the Oral Drugs

Metformin continues. Glipizide, a sulfonylurea, increases the risk of hypoglycemia, especially combined with insulin and irregular meals. I reduce glipizide to 5 mg twice daily now and plan to stop it once his fasting glucose approaches target.

Life on the Road

Insulin must stay cool. Mr. W. will keep his in-use pen at room temperature for up to 28 days and store spare pens in a small refrigerator or insulated cooler in the cab, never in direct sun or a freezing cab. He will carry glucose tablets within reach of the driver's seat and in his jacket. We plan meals he can buy at truck stops, with a protein and a vegetable at each, and discuss avoiding long stretches without food.

His License

Federal rules adopted in 2018 allow drivers with insulin-treated diabetes to be medically certified if a treating clinician completes an assessment confirming a stable insulin regimen and proper control, and the driver keeps glucose records. I will complete that assessment when his regimen is stable and send it to his medical examiner. He should not drive if his glucose is below 100 mg/dL without eating first and rechecking, and he must never drive during or right after a low. A continuous glucose monitor would make this easier and I will seek coverage for it.

Recognizing and Treating Lows

He will learn the signs of hypoglycemia, including shakiness, sweating, confusion and irritability, and the rule of 15: 15 grams of fast sugar, recheck in 15 minutes and repeat if still low. His wife will learn to use glucagon, which he will keep at home and in the cab.

Monitoring

He will check fasting glucose daily and before driving each shift, and send readings through the patient portal weekly while titrating. I will call at one week and see him at four weeks. A1C will be repeated in three months. Weight, kidney function and eye and foot examinations continue on their usual schedule.

Why Not Start a GLP-1 Receptor Agonist Instead?

A GLP-1 receptor agonist would lower glucose, promote weight loss and cause little hypoglycemia on its own, and for many patients it is a reasonable first injectable. For Mr. W., the unintended weight loss, thirst and nocturia point to a degree of insulin deficiency that is better addressed directly. Nausea, common when these drugs start, would also be unwelcome on long drives. Once his glucose is controlled, adding a GLP-1 receptor agonist could allow a lower insulin dose and help with weight, and I will raise it at the three-month visit.

If the Fasting Glucose Reaches Goal but the A1C Does Not

Some patients reach their fasting targets while daytime glucose stays high after meals. If Mr. W.'s A1C remains above goal after three months with fasting values in range, the next step would be addressing post-meal glucose, with a GLP-1 receptor agonist or a single dose of mealtime insulin at his largest meal, rather than continuing to raise the basal dose. The ADA standards caution against overbasalization, a basal dose climbing well above 0.5 units/kg a day without better control (American Diabetes Association Professional Practice Committee, 2024).

Teaching Injection Technique

I teach pen use with a demonstration and return demonstration, including priming, rotating sites in the abdomen and thighs and disposing of needles in a hard container kept in the cab.

Sick Days

If he becomes ill on the road and cannot eat, he should keep taking glargine, since his body still needs basal insulin, but check glucose every four hours, drink fluids, skip glipizide and call the clinic. Metformin should be held if he is vomiting or dehydrated.

Conclusion

Mr. W.'s A1C, symptoms and weight loss meet the guideline's criteria for starting insulin. Basal insulin was chosen because it causes fewer lows than prandial regimens, and glargine over NPH because it causes less nocturnal hypoglycemia at a similar A1C. A self-titration plan, reduced sulfonylurea, road-ready storage and snacks and a clear path to keeping his license make the plan fit the life he actually leads.

References

American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Suppl. 1), S158-S178. https://doi.org/10.2337/dc24-S009

Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009). Three-year efficacy of complex insulin regimens in type 2 diabetes. New England Journal of Medicine, 361(18), 1736-1747. https://doi.org/10.1056/NEJMoa0905479

Riddle, M. C., Rosenstock, J., Gerich, J., & Insulin Glargine 4002 Study Investigators. (2003). The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care, 26(11), 3080-3086. https://doi.org/10.2337/diacare.26.11.3080